Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Several anticancer drugs including methotrexate (MTX) cause serious lung diseases such as pulmonary fibrosis. Although evidences showing the association of epithelial-mesenchymal transition (EMT) with pulmonary fibrosis are increasing, the mechanism underlying anticancer drug-induced EMT has been poorly understood. In this research, we indicated that MTX-induced EMT may be related to cell cycle arrest in human alveolar epithelial cell line, A549. It was also suggested that the transforming growth factor (TGF)-β-related signaling pathway may partly be involved in MTX-induced EMT, and MTX may induce EMT via upregulation of ATF3 expression and increase of PAI-1 secretion followed by interaction of PAI-1 with uPAR
|